Rohan Dixit is founder and CEO of Lief Therapeutics, a mental health telemedicine company built around a breakthrough wearable device. Formerly a Harvard and Stanford neuroscientist, his work has been featured on The Today Show, CNBC, NBC, and CBS, and in The Atlantic and Forbes magazine. His primary focus for the past 13 years has been the intersection between mind-body interventions, science, and technology. As a repeat healthcare entrepreneur, Rohan has created wearable device products that monitor and augment mind-body interventions and have been used by thousands of consumers and patients.
Rohan Dixit
Founder and CEO
ABOUT THE INNOVATION CHALLENGE
Patient Entrepreneurs with innovative companies in early stages of development will receive an invitation to pitch their solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders.
The winner will be awarded a $25,000 monetary grant. Additionally, competing finalists will be considered for possible partnerships/investments with/by Orexo.
The Lyfebulb–Orexo Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).
SHARE
Honorable Mention
I Ally
When Lucinda became her father’s caregiver at a young age, she struggled with the lack of resources available to her. Taking matters into her own hands, she created I Ally, an app for family caregivers that provides access to mutual aid, mental health services, financial & legal counsel, and peer support. She is a Founding Member of Tech Ladies, owns the social media marketing agency Got It Done Gal, and premiered a short film, Laura Point, at the Cannes Film Festival in 2016. Mrs. Koza is a committed advocate, speaker and thought leader on family caregiving, being a young caregiver, and the role of digital healthcare technology in transforming patient experience.
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine, transplantation, and chronic cough.
Orexo DTx is the digital health arm of Orexo AB, a pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies. The company addresses unmet needs mainly within the growing space of addiction. Orexo DTx was created in Q4 of 2019 and currently has three products in the pipeline, vorvida® for alcohol misuse, deprexis® for depression, and OXD01 for opioid use disorder, all in partnership with the GAIA group.
Orexo DTx’s mission is to redefine treatment of addiction by offering clinically validated digital therapeutics to ensure more successful treatment for patients and cost-effective solutions for payers. The digital products will be commercialized by Orexo DTx worldwide, with the U.S. as the principal market, where Orexo also commercializes its lead product Zubsolv® (buprenorphine and naloxone) sublingual tablets (CIII) for treatment of opioid use disorder.
Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the U.S. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
Join us for an informal, chat-style discussion between two Lyfebulb community members in recovery, Rebecca Rush & Lisa Smith, lightly moderated by Lyfebulb CEO Karin Hehenberger, MD, PhD. We are all living during unprecedented times created by the COVID-19 pandemic, which has posed particular challenges for the addiction recovery community. Do you want to hear how others in recovery have adapted to the new normal? This event, part of our fireside chat series, will spotlight innovative solutions and adaptations for a quarantined reality in order to maintain recovery. We will be sure to discuss today’s addiction and recovery landscape as a whole, so we encourage you to submit any specific discussion topics or questions that you’d like us to cover!
See the replay here:
Time: Aug 26, 2020 04:30 PM EST
“Part of adapting to the conditions of the pandemic has meant refocusing the tools I rely on for accountability and keeping to a routine. In this context, this may mean pulling out different tools than you are used to relying on.” – Lisa Smith
Winning Entry to Receive $25,000 Grant
UPPSALA, SWEDEN, AND NEW YORK, NY, USA, June 17th, 2020: Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substance Use Disorder is now accepting applications. The goal of the initiative is to seek novel digital solutions, in early stages of development, to address unmet needs in supporting successful, long-term recovery from alcohol and opioid use disorders.
The Innovation Challenge will take place in October 2020 and will be open to Patient Entrepreneurs—those who have been directly affected by a substance use disorder him/herself, or as a support partner for a loved one. Selected finalists will receive an invitation to pitch their digital solutions, virtually, to an expert panel of judges comprised of healthcare industry, medical and patient leaders. Competing finalists will be considered for possible partnerships with Orexo or for investment. The winner will be awarded a $25,000 monetary grant.
“The complex and intimate journey each person undergoes along the road to recovery for alcohol misuse or opioid addiction lends itself well for the patient and his/her care partners to become mentors or even innovators.” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Patient Entrepreneurs experience firsthand the gaps in existing treatments and are solving for better solutions to address those unmet needs. One cannot underestimate the role personal connections have in this space; to scale this approach and provide 24/7 support no matter where the people reside, digital technologies are critical tools for lasting solutions.”
“The COVID-19 pandemic has propelled the growth of the already increasing and prominent substance abuse patient group globally. This development is expected to continue over years to come, as the result of isolation and economic downturn. To fully address these developments, it is pivotal to understand the unmet needs of the patients on their road to recovery. Nobody can do this better than patients themselves and their care partners.” said Mikaela Odlander, Director of Digital Therapeutics at Orexo. “This innovation challenge will support Orexo in our continuous strides towards combatting substance use disorder through the use of digital therapeutics.”
Patient entrepreneurs may apply now through Friday, July 31, 2020 at 11:59 p.m. EDT at https://lyfebulb.com/innovation-award/orexo-2020. The competition is free to enter. Official eligibility criteria, and terms and conditions can be found on the Lyfebulb website.
About Digital Therapeutics
Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. Digital therapeutics are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. (As defined by Digital Therapeutics Alliance)
About Orexo DTx
Orexo DTx is the digital health arm of Orexo AB, a pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies. The company addresses unmet needs mainly within the growing space of addiction. Orexo DTx was created in Q4 of 2019 and currently has three products in the pipeline, vorvida® for alcohol misuse, deprexis® for depression, and OXD01 for opioid use disorder, all in partnership with the GAIA group.
Orexo DTx’s mission is to redefine treatment of addiction by offering clinically validated digital therapeutics to ensure more successful treatment for patients and cost-effective solutions for payers. The digital products will be commercialized by Orexo DTx worldwide, with the U.S. as the principal market, where Orexo also commercializes its lead product Zubsolv® (buprenorphine and naloxone) sublingual tablets (CIII) for treatment of opioid use disorder.
Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the U.S. The company is headquartered in Uppsala, Sweden, where research and development activities are performed. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
About Lyfebulb
Lyfebulb is a chronic disease-focused patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine and transplantation.
NEW YORK, NY, USA, July 15, 2020: Lyfebulb, a patient empowerment platform, in partnership with Orexo, a global leader in the addictive disorders field, invites entrepreneurs to apply now through August 7th for the Lyfebulb-Orexo Innovation Challenge. The goal of the initiative is to bring together new solutions to address unmet needs in supporting successful, long-term recovery from alcohol and opioid use disorders.
Submissions may span not only digital health solutions, but also consumer products, telehealth, mobile health, health information technology, personalized care, and devices, sensors and wearables that support all facets of recovery.
“These business concepts may directly treat the substance use disorder or be used in tandem with treatment to foster healthy habits and routines, improve mental and physical well-being, or address co-morbidities of the disorders,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Solutions should improve outcomes and experiences for either those struggling with addiction or their support partners; both parties are critical to maintain long-term success.”
The Innovation Challenge will take place, virtually, in October 2020 and will be open to Patient Entrepreneurs—those who have been motivated by a personal health experience of him/herself, or as a support partner for a loved one. Selected finalists will receive an invitation to pitch their solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. Competing finalists will be considered for possible partnerships with Orexo or for investment. The winner will be awarded a $25,000 monetary grant.
Patient entrepreneurs may apply now through Friday, August 7, 2020 at 11:59 p.m. EDT at https://lyfebulb.com/innovation-award/orexo-2020. The competition is free to enter. Official eligibility criteria, and terms and conditions can be found on the Lyfebulb website.
About Lyfebulb
Lyfebulb is a chronic disease-focused patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine, transplantation and chronic cough.
Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the U.S. The company is headquartered in Uppsala, Sweden, where research and development activities are performed. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
When Lucinda became her father’s caregiver at a young age, she struggled with the lack of resources available to her. Taking matters into her own hands, she created I Ally, an app for family caregivers that provides access to mutual aid, mental health services, financial & legal counsel, and peer support. She is a Founding Member of Tech Ladies, owns the social media marketing agency Got It Done Gal, and premiered a short film, Laura Point, at the Cannes Film Festival in 2016. Mrs. Koza is a committed advocate, speaker and thought leader on family caregiving, being a young caregiver, and the role of digital healthcare technology in transforming patient experience.
Rohan Dixit is founder and CEO of Lief Therapeutics, a mental health telemedicine company built around a breakthrough wearable device. Formerly a Harvard and Stanford neuroscientist, his work has been featured on The Today Show, CNBC, NBC, and CBS, and in The Atlantic and Forbes magazine. His primary focus for the past 13 years has been the intersection between mind-body interventions, science, and technology. As a repeat healthcare entrepreneur, Rohan has created wearable device products that monitor and augment mind-body interventions and have been used by thousands of consumers and patients.
At the age of 19 years old, Seth became severely addicted to heroin and other hard drugs. After three years and nine overdoses he decided he was going to get clean. After kicking this habit cold, he addressed the underlying emotional issues that spurred the addiction and never used again. That was 22 years ago. Seth Leaf Pruzansky was born with the ability to interpret profound wisdom from his soul. Throughout the course of his life he has learned how to masterfully articulate this knowing in a way that benefits those who are looking for real answers to the big questions in life.
Seth has spent countless hours in meditation since he was a child, including a “forced” and extended meditation retreat in federal prison. He has faced and survived severe opiate addiction, childhood bullying, chronic illness, financial collapse, and so many other hardships, eventually going on to thrive.
He has taken the development of his inner state and applied it successfully to the world at large through “conscious-preneurship.”
Co-owner/founder of Tourmaline Spring-the highest quality most ethically produced bottled water on earth. www.tourmalinespring.com
Co-owner/founder of the certified organic raw food snack company Living Nutz www.livingnutz.com
A soon to be published author of the book “The Fight to Enlight” and Editor of a blog dedicated to transforming human consciousness www.imawakenowwhat.com
Olivia Pennelle is a writer, journalist, and recovery activist. Her work has appeared in STAT News, Insider, Filter Magazine, Ravishly, The Temper, and Shondaland. She is the founder of popular site Liv’s Recovery Kitchen. She lives near Portland, Oregon.
Jesse is both a non-drinker and founder of The Mocktail Project, a mission based project helping to create a safer, more inclusive, stigma-free drinking culture. Jesse began his career in business consulting, helping streamline small business needs. In 2017, on his sobriety date, Jesse walked away from the comforts of his corporate life to start his newest journey in his professional career, The Mocktail Project.
In 2017, in conjunction with the start of his newly formed mission, Jesse traveled cross-country for more than two years. He achieved his goal of visiting all 48 lower states in early 2019. His personal goal during this time was to try new activities he once thought were impossible to do while sober. Professionally, he wanted to embrace new ideas and spark new conversations around sobriety and the alcohol-free community. Today, Jesse leads national campaigns in the alcohol-free community partnering with big spirit brands. This fall, The Mocktail Project will be introducing the first mobile mocktail bar in Bourbon Country. On 4.16.2020 Jesse celebrated six years of active recovery & three years since forming The Mocktail Project. In that time, The Mocktail Project has crafted and served more than 35,000 alcohol-free cocktails for those choosing not to imbibe.
Avery Nix is in long-term recovery from substance use disorder. Being in recovery means he is a proud father to his 7-year-old daughter and son who is almost 2 years old, and a loving fiancé who shares a similar vision for their life together. He serves his local community in several different capacities, as well as the state of Georgia at large, but his heart and soul rests in advocating for people in self-discovery and seeking long-term recovery.
He grew up in Clermont, Georgia, just north of Gainesville. In high school, Avery played football, wrestled, and ran track. He acquired many followers during these years and left an impact on his community. This began laying the groundwork for his journey to personal recovery and his career in the field of addiction recovery. Today, Avery finds himself advocating for high school athletes that struggle with substance use disorder. He has spoken on many different platforms, both nationally and locally, including WebMD, local newspapers and podcasts. Avery also arranges an annual flag football event to raise awareness for all pathways to recovery.
Avery has 5 years in continuous recovery. In that time, he has helped pilot and launch peer recovery coaching, with the GA Council on Substance Abuse, in the emergency departments of Northeast GA Medical Center. As of late September 2018, he took a position working with adolescents as the Director of Marketing and Clinical Outreach for Eagle Overlook Recovery for Adolescents.
He continues to spread as much hope and awareness as possible for those in recovery or seeking recovery from substance use disorder and mental illness. His priority is to support those who need it most.
